PULMATRIX, INC. Business Acquisition, Pro Forma Revenue
PULMATRIX, INC. (PULM) reported Business Acquisition, Pro Forma Revenue of $1.20 million for the 12-month period ending 2015-12-31, per its 10-K filed 2017-03-10.
Discontinued › Income Statement › Other Income
us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2017-03-10
- PULMATRIX, INC. business acquisition, pro forma revenue for the quarter ending 2015-12-31 was $275.00K, a 12.42% decline year-over-year.
- PULMATRIX, INC. business acquisition, pro forma revenue for the quarter ending 2015-09-30 was $651.00K, a 2070.00% increase year-over-year.
- PULMATRIX, INC. business acquisition, pro forma revenue for the quarter ending 2015-06-30 was $170.00K.
- PULMATRIX, INC. business acquisition, pro forma revenue for the quarter ending 2015-03-31 was $105.00K.
- PULMATRIX, INC. business acquisition, pro forma revenue for fiscal 2015 was $1.20M, a 241.19% increase from fiscal 2014.
- PULMATRIX, INC. business acquisition, pro forma revenue for fiscal 2014 was $352.00K.
| Period end | Business Acquisition, Pro Forma Revenue 3 month | Business Acquisition, Pro Forma Revenue 6 month | Business Acquisition, Pro Forma Revenue 9 month | Business Acquisition, Pro Forma Revenue 12 month |
|---|---|---|---|---|
| 2015-12-31 | $275.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | $926.00K derived: sum of 2 quarters · filed 2017-03-10 | $1.10M derived: sum of 3 quarters · filed 2017-03-10 | $1.20M 10-K · filed 2017-03-10 |
| 2015-09-30 | $651.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $821.00K derived: sum of 2 quarters · filed 2016-08-04 | $926.00K 10-Q · filed 2015-11-12 | $1.24M derived: sum of 4 quarters · filed 2016-08-04 |
| 2015-06-30 | $170.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $275.00K 10-Q · filed 2016-08-04 | $589.00K derived: sum of 3 quarters · filed 2016-08-04 | $619.00K derived: sum of 4 quarters · filed 2016-08-04 |
| 2015-03-31 | $105.00K 10-Q · filed 2016-05-05 | $419.00K derived: sum of 2 quarters · filed 2016-05-05 | $449.00K derived: sum of 3 quarters · filed 2016-05-05 | |
| 2014-12-31 | $314.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10 | $344.00K derived: sum of 2 quarters · filed 2016-03-10 | $352.00K 10-K · filed 2016-03-10 | |
| 2014-09-30 | $30.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $38.00K 10-Q · filed 2015-11-12 | ||
| 2014-06-30 | $8.00K 10-Q · filed 2015-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |